Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression

Germetaki, Theodora, Nicholls, Camille, Adams, Richard A ORCID: https://orcid.org/0000-0003-3915-7243, Braun, Michael, Rogan, Jane, Moghadam, Sharzad, Lenfert, Eva, Lukas, Antje, Edelstein, Daniel L, Jones, Frederick S and Saunders, Mark P 2020. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncology 16 (28) , pp. 2177-2189. 10.2217/fon-2020-0523

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB)

Abstract

Aim: To determine the concordance between plasma and tissue RAS mutation status in metastatic colorectal cancer patients to gauge whether blood-based testing is a viable alternative. We also evaluated the change in mutation status on progression. Materials/methods:RAS testing was performed on plasma from patients commencing first-line therapy (OncoBEAM™ RAS CEIVD kit). Results were then compared with formalin-fixed paraffin embedded tumor samples. Results: The overall percentage agreement (concordance) was 86.0% (86/100), which demonstrates that blood-based testing is an alternative to tissue-based testing. Reproducibility was 100% between three laboratories and 20% showed changes in their RAS mutational status on progression. Conclusion: These results show good concordance between tissue and plasma samples and suggest the need for longitudinal plasma testing during treatment to guide management decisions.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Future Medicine
ISSN:	1479-6694
Date of First Compliant Deposit:	13 May 2021
Date of Acceptance:	2 July 2020
Last Modified:	08 May 2023 10:50
URI:	https://orca.cardiff.ac.uk/id/eprint/141030

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item